Provided by Tiger Fintech (Singapore) Pte. Ltd.

Phio Pharmaceuticals

2.73
+0.03001.11%
Post-market: 2.770.0393+1.44%19:59 EDT
Volume:1.64M
Turnover:4.65M
Market Cap:13.04M
PE:-0.30
High:3.05
Open:2.71
Low:2.70
Close:2.70
Loading ...

Phio Pharmaceuticals Unveils $3.2 Million Registered Direct Offering; Shares Fall

MT Newswires Live
·
15 Jan

Phio Pharmaceuticals Corp trading resumes

TIPRANKS
·
14 Jan

Phio Pharmaceuticals Corp trading halted, volatility trading pause

TIPRANKS
·
14 Jan

Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Newsfile
·
14 Jan

Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge

Benzinga
·
14 Jan

Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why

Benzinga
·
14 Jan

Phio Pharma Shares Triple After Positive Trial Data for Cancer Treatment

Dow Jones
·
13 Jan

Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762

Newsfile
·
13 Jan

Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology

Newsfile
·
02 Jan

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Newsfile
·
24 Dec 2024

Investors Look to Reverse Last Week's Slide as US Futures Mixed Monday Pre-Bell

MT Newswires Live
·
23 Dec 2024

Why Rumble Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket

Benzinga
·
23 Dec 2024

Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Newsfile
·
20 Dec 2024

BRIEF-Phio Pharmaceuticals Positive Safety Monitoring Committee Recommendation To Continue To Third Dose Cohort In Its Clinical Study Of Ph-762

Reuters
·
19 Dec 2024

Phio Pharmaceuticals: Positive Safety Monitoring Committee Recommendation to Continue to Third Dose Cohort in Its Clinical Study of Ph-762

THOMSON REUTERS
·
19 Dec 2024

Phio Pharmaceuticals Corp: Intratumoral Injections Have Been Well Tolerated

THOMSON REUTERS
·
19 Dec 2024

Phio Pharmaceuticals Corp: No Dose-Limiting Toxicities, or Serious Adverse Events in Participants Receiving Intratumoral Ph-762

THOMSON REUTERS
·
19 Dec 2024

Phio Pharmaceuticals Safety Panel Approves Dose Escalation in Skin Cancer Trial

MT Newswires Live
·
19 Dec 2024

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762

Newsfile
·
19 Dec 2024

Phio Pharmaceuticals Announces Publication in Frontiers in Immunology

Newsfile
·
12 Dec 2024